Ignite Creation Date:
2024-07-17 @ 11:02 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06467097
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-06-11
Brief Title:
Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
A Phase Ⅲ Randomized Study Systemic Treatment Alone Versus Systemic Treatment Plus Stereotactic Abative Body Radiotherapy for Patients With Oligometastatic Renal Cell Carcinoma SABLOR Study
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SABLOR
Brief Summary:
To evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma including inductive oligometastases along with standard systemic therapy contributes to improved progression-free survival rates for patients
Detailed Description:
Various institutions are attempting to use locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma accompanied by a few metastases Research findings have indicated that high-dose locoregional radiotherapy can suppress disease progression potentially prolonging the interval for additional systemic therapy however whether the addition of locoregional radiotherapy in cases of renal cell carcinoma with oligometastases demonstrates superior oncologic outcome compared to standard systemic therapy alone has yet to be established Therefore a randomized phase III study is being conducted to evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma including inductive oligometastases along with standard systemic therapy contributes to improved progression-free survival rates for patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None